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ABSTRACT
للعالج  النسيجية  االستجابة  حتديد  أجل  من  األهداف:  
وتقييم  الورم  نخر  من  لنسبة  اجلراحية  العملية  قبل  الكيميائي 
الصلة بني االستجابة النسيجية والنتائج الورمية.
الطريقة:  متت معاجلة، وإجراء عملية االستئصال، وتلقي العالج 
الكيميائي قبل وبعد العملية لثمانني مريضًا مصابًا بالورم العظمي 
اللحمي، مبستشفى شافا يحيان – إيران، خالل الفترة ما بني عام 
2003م وحتى عام 2005م.  مت فحص كل العينات املستأصلة التي 
أجريت لها العملية اجلراحية، وحتديد درجة االستجابة النسيجية 
للعالج الكيميائي قبل العملية.  نخر من الدرجة األولى لنسبة 
%50 من الورم أو أقل، نخر من الدرجة الثانية ألكثر من 50%، 
من  النخر ألكثر  من  الثالثة  الدرجة   ،90% نسبة  من  اقل  ولكن 
.90%
النتائج:  كانت الفترة الفعلية للمتابعة للمرضى الناجيني الذين 
االستجابة  يومًا.    1044 املرض  من  خالية  حالتهم  استمرت 
النسيجية للعالج الكيميائي قبل العملية )p=0.016(، وكانت 
معدل  بلغ  املرض.   من  اخلالية  للنجاة  أهمية  التنبؤات  أكثر 
مريضًا  لثمانني  قصيرة  لفترة  املرض  من  اخلالية  النجاة  حدوث 
%86 )69 مريض( عند الشهر الثاني عشر، و%50 عند الشهر 
الرابع والعشرون )24 مريض(، و%21 )5 مرضى( عند الشهر 
األربعون، مع جناة خمسة مرضى ملتوسط 1096 يومًا.
خامتة:  تعتبر االستجابة النسيجية للعالج الكيميائي قبل العملية 
العظمي  للورم  العملية  عالج  لنتيجة  مهم  سريري  تنبؤ  عامل 
املرضى  حتديد  أجل  من  العامل  هذا  استعمال  يجب  اللحمي.  
الذين لديهم خطورة عالية من انتشار املرض، حيث أن مثل هؤالء 
املرضى قد يكونوا مرشحني للمزيد من للعالج املكثف.
Objective: To determine the histological response 
to preoperative chemotherapy of the percentage of 
tumor necrosis, and to assess the relationship between 
the histological response and the oncological result.
Methods: Eighty patients with osteosarcoma were 
managed with preoperative and postoperative 
chemotherapy and operative resection at Shafa 
Yahyaeeyan Hospital, Tehran, Iran between 
2003-2005. Sections of each operative specimen 
were examined, and the histological response to 
chemotherapy was graded. Grade 1 indicated necrosis 
of 50% of the tumor or less; grade 2, necrosis of more 
than 50% yet less than 90%; grade 3, necrosis of more 
than 90%.
Results: The mean duration of the follow-up of the 
surviving patients, who were continuously free from 
disease was 1044 days. The histological response to 
preoperative chemotherapy (p=0.016) was the most 
important predictor of event-free survival. The rate 
of event-free short-term survival for the 80 patients 
entering this study was 86% (69 patients) at 12 
months, 50% (24 patients) at 24 months, and 21% 
(5 patients) at 40 months, with 5 patients surviving 
for a median of 1096 days.
Conclusion: The histological response to preoperative 
chemotherapy is an important clinical predictor of 
the result of operative treatment of osteosarcoma. 
This indicator should be used to identify patients who 
are at high risk for metastasis, as such patients may be 
candidates for more intensive or novel therapy.
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Osteosarcoma is the most frequent primary malignant bone tumor, originating often in 
the metaphyses of long bones of adolescents.1 The 
interdisciplinary treatment concept including the 
aggressive polychemotherapy, has lead to dramatic 
prognostic improvement in young patients with 
localized extremity disease, with relapse free survival 
rates of approximately 50-80% as reported by 
specialized centers or multicentric groups.1-16 The 
uniform treatment concept of pre- and postoperative 
chemotherapy in combination with aggressive surgery 
has formed the basis of all consecutive neoadjuvant 
study protocols since 1980.16 
Methods. Eighty patients who met the inclusion 
criteria were enrolled in this study between 2003-
2005. They were managed for osteosarcoma at Shafa 
Yahyaeeyan Hospital, Tehran, Iran received similar 
chemotherapy protocol. Patients with osteosarcoma 
as a secondary malignancy or recurrent disease, and 
patients who had both irradiation and chemotherapy, 
were all excluded from the study. As radiation therapy 
plus chemotherapy before operation increases the extent 
of tissue necrosis, and it biases the comparisons of 
patients getting chemotherapy, plus radiation therapy 
with chemotherapy alone, so all patients who received 
radiation therapy plus chemotherapy, were all excluded 
from the study. The follow up of the patients who were 
alive and free from disease was between 200-1200 
days with mean follow up of 1044 days. The mean age 
of diagnosis of the disease was 15.6 years (standard 
deviation 3.7), range from 8-24 years. There were 6 
upper limb and 74 lower limb involvements of tumor, 
and 41 cases had proximal limb tumor.
The initial evaluation of all patients included the 
recording of the medical history, physical examination, 
and hematological studies, procedures used to define the 
extension of the primary tumor including conventional 
radiography in all cases. A negative chest x-ray and 
negative TC-99 methylene diphosphonate bone 
scan are required for exclusion of primary metastasis. 
During the follow up, radiogram of the chest, and the 
primary tumors were to be repeated at regular intervals 
specified in the respective treatment protocol. The size 
of the tumor was estimated by measuring its largest 
available dimension on radiographic image that had 
been made before treatment, or by determining the 
maximum size of the restricted tumor with pathological 
examination. Pre- and postoperative chemotherapy 
were to be given to all patients. All protocols included 
high doses of methotrexate with leucovarin rescue, in 
addition, doxorubicine, cisplatin isophosphamide, and 
bleomycin, cyclophosphamide, and dactinomycin were 
used in varying combinations. The scheduled duration 
of chemotherapy ranged from 24-38 weeks. Definitive 
surgery was scheduled to take place between ninth and 
seventeenth weeks.16 The type of surgery was specified 
as amputation, wide resection, and marginal resection. 
This study was approved by the Ethical Committee of 
Iran University of Medical Science, Iran.
Histological studies. The histological diagnosis of 
osteosarcoma was based on the results of open biopsy or 
needle biopsy. Hematoxylin and eosin as well as periodic 
acid Schiff were used to detect the tissue sections. 
Determination of the percentage of tumor necrosis. 
Each resected specimen was bisected, and the perimeter 
of the tumor was defined grossly. The entire area of the 
bisected tumor was partitioned into blocks of tissue 
averaging 2 cm2 en face. All areas of the specimen, 
including the medullary canal, residual cortical bone, and 
surrounding soft tissue were included, and histological 
slides were prepared from these blocks. The extent of 
the necrosis was graded relative to the percentage of 
residual viable tumor in a semiquantitative manner, 
described by Huvos17 and Rosen et al.18 A grade one 
histological response was characterized by little or no 
necrosis (involving 50% of the tumor or less), a grade 2 
response by necrosis more than 50% yet less than 90% 
of the tumor, and a grade 3 response by only scattered 
foci of viable tumor cells (necrosis more than 90%). The 
histological response to preoperative chemotherapy was 
determined retrospectively by the same pathologist in a 
blind fashion. Statistical analysis was performed using 
SPSS Version 15 for windows.
Results. The rate of event free short-term survival 
for 80 patients entering study was 86% (69 patients) at 
12 months, 50 % (24 patients) at 24 months, and 21% 
(5 patients) at 40 months ,whereas 5 surviving patients 
were followed for median  of 1096 days (Figure 1). In 
our study, we had 50 males, and 30 females patients, 
the median age of admission was 15 years (7-47 years). 
Femur was the most frequent location of tumor with 42 
cases (53%), and tumors of tibia was 32 cases (40%), 
and humerus was 6 cases (7%). The mean was 12.7 
cm and median was 14 cm diameters of tumors (8-25 
cm). We had 11 amputations, 65 wide resections, and 
Disclosure. This work was supported in part by Grants-
in-Aid for scientific research from the Orthopedic 
Department, Iran University of Medical Sciences and 
Department of Cellular and Molecular Research Center, 
Iran University of Medical Science .
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4 marginal resections. Most of the local recurrences 
(72%, 18 out of 25 patients) manifested within 2 years. 
Only 4 patients were followed more than 3 years in our 
short-term study. 
Histological response to preoperative chemotherapy.
Histological analysis of the 80 primary tumors after 
preoperative chemotherapy showed that 41 (51.3%) 
had nearly completed response (grade 3 necrosis of 
90-99% of the tumor). In contrast, 22 tumors (27.5%) 
demonstrated little or no response (grade one necrosis 
of 50% or less), and 17 tumors (21.3%) exhibited a 
moderate response (grade 2 necrosis of more than 50% 
yet less than 90%). We did not find any significant 
association between a good response (less than 10% 
possible tumor) to chemotherapy, and probable factors 
affecting tissue necrosis such as age, gender, and tumor 
size. (p>0.05, chi squared test).
Factors affecting event-free survival. The grade of 
histological response was strongly associated with event-
free survival (p=0.00001, Figure 1). The difference in 
event-free survival of the patients who had good (grade 
3) histological response, and those who had grade 
one p=0.00001, or grade 2 p=0.0004 response was 
significant, however, difference in event-free survival of 
grade one and 2 was not significant (p=0.07). The rate 
of event-free survival at 3 years was 3-22 who had grade 
one necrosis, 10 of 17 who had grade 2 necrosis, and 40 
of 41 who had grade 3 necrosis (Figure 2).
Eighty tumors were classified into 2 groups 
according to whether one dimensional size of the tumor 
(the median measurement) was 14 cm or less, or greater 
than 14 cm (range of size, 8-25 cm). At 3 years, the rate 
of  short term event-free survival was 69% (40 out of 58 
patients) for patients who had a small tumor compared 
with 59.1% (13 out of 22 patients) for those who had 
a large tumor (Figure 3). The difference between these 
2 groups was not significant (p=0.82). Distal tumors 
tended to be greater than proximal lesions, their 
difference was significant (p=0.0001, Mann-Whitney 
test). Event-free survival was 70.8% (29 of 41 patients) 
for proximal located tumors, and 61.5% (24 out of 
Figure 1 - The survival of all patients (the end point is death or recurrence 
of disease).
Figure 2 - The survival of patients according to the percent of tissue 
necrosis.
Figure 3 - The survival of patients according to the categorized size of 
tumor.
Table 1 - Logistic regression model showing the effect of tissue necrosis 
on survival. 
Variables P-value Odds ration
Tissue necrosis     0.016* 16.67
Operation kind NS 3.0
Metastasis NS 2.2
Constant NS 1.2
 *Significant <0.05, NS - non significant
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39 patients) for distally located tumors, however, their 
short-term event-free  survivals were not significant, 
(p=0.95). The variables that found to predict overall 
survival in univariate analysis, were the histological 
response of the primary tumor to preoperative 
chemotherapy (p=0.0001) and metastasis during or 
after chemotherapy (p=0.00001). Combining these 2 
factors in a logistic regression model, we developed a 
table for the chance of surviving or death. We did not 
use cox model for multivariable analysis as the risk of 
death is not constant during the study, in this model 
tissue necrosis grade 3 was a significant predictor of 
overall survival (Figure 4). 
Other factors used in univariate analysis were aged 
at admission, location of tumor at tibia comparing to 
the other sites, proximal tumor site, however, none of 
them had significant effect on short-term event-free 
survival also due to the 2 metastasis at presentation, it 
was not possible to study the effect of these variables on 
survival. 
Factors in relation with tissue necrosis and systemic or 
local relapse. Age at admission, gender, tumor size, tibia 
location of tumor versus other areas, and time interval 
until operation did not have stochastic significance 
on tissue necrosis or systemic relapse in all univariate 
analyses (p>0.05, Chi squared test). Patients with more 
than 90% tissue necrosis had less systemic recurrences 
that were significant (p=0.0001, Chi squared test) 
Discussion. Operative treatment for the local 
control of osteosarcoma provides an opportunity to 
examine the histological response of the primary tumor 
to the preoperative chemotherapy, and the relationship 
between the histological response and oncological 
result. As spontaneous necrosis is slight in untreated 
tumors of osteosarcoma, rarely exceeding 25% in 
osteosarcoma,19 it should not affect the measurement 
of chemotherapy induced tumor necrosis. In patients 
who have osteosarcoma of the extremities, the extent of 
tumor necrosis, as determined histologically, is the most 
important prognostic factor in the prediction of systemic 
disease after intravenous chemotherapy.12,18,20-25 Patients 
who had completed (grade 4) necrosis, or only scattered 
foci of possible tumor cells (grade 3 necrosis) were 
considered to have a good response to chemotherapy 
at 3 years, and the rate of event-free survival for these 
patients was superior to that for patients who had (grade 
one) or (grade 2) necrosis. Other variables with possible 
prognostic impact include tumor size,26 gender,27 older 
age,27 younger age,8,28 proximal tumor site,6,13 high 
alkaline phosphatase,10,29 and high lactate dehydrogenase 
values,10,30 and location of tumor at tibia.  In our study, 
patients  without metastasis during or after therapy or 
with tissue necrosis more than 90% had longer survival 
and less death during short-term follow up (40 months) 
and in combined form of these variables, grade 3 tissue 
necrosis predicts less death and longer survival, and so a 
good response to chemotherapy (less than 10% possible 
tumor) is an important prognostic factor for short-
term survival in comparing with systemic recurrence, 
during or after therapy. Like other issues, tissue necrosis 
predicts systemic disease well after chemotherapy. We 
did not find any significant effect for other variables 
such as gender, age, proximal tumor site, and the 
location of tumor at tibia in comparing with other sites, 
on systemic recurrence. Patients with greater degrees of 
post chemotherapy tissue necrosis have reduced chance 
of having metastases, so this relationship between 
histologic response and prognosis suggests that the 
effect of chemotherapy on the primary tumor correlates 
with the effect on the micrometastatic disease. Different 
approaches in treatment of patients after poor response 
to chemotherapy12,31-34 by using another chemotherapy 
regimen after surgery, have usually failed.33-34 Thus, 
it is important if there are factors that influence the 
histologic response to preoperative chemotherapy or 
to know what combination of drugs is most effective. 
Unfortunately, in treatment of osteosarcoma, there 
have been few studies investigating factors that could 
influence the histologic response of a primary tumor 
to chemotherapy.35,36 In a previous study of only 247 
patients preoperatively treated with a 3 drug regimen 
(methotrexate, cisplatin, and doxorubicin), the grade 
of histologic response to chemotherapy was related to 
histologic response of the tumor to the methotrexate 
serum peak at the end of infusion.36 As we had chosen 
3 cycles of preoperative chemotherapy protocols for 
nearly all of the patients, and our patients’ histological 
subtypes of the tumors were not identified, so it was not 
possible for us to look for the effect of these 2 factors on 
tissue necrosis. The effect of other possible variables on 
tissue necrosis age, gender, and site of primary tumor 
was searched in this study, although none of them had a 
significant effect on post chemotherapy tissue necrosis. 
Although we did not find a significant relationship 
between tumor size and tissue necrosis, we cannot 
discuss against the hypothesis of Goldie and Coldman 
which explains that larger tumors are associated with a 
higher risk of an inadequate response to chemotherapy 
due to the presence or development of drug resistant 
clones.37 Larger tumors are expected to have more 
micro metastasis and systemic relapse, however, we 
did not find significant relationship between tumor 
size and metastasis during, or after therapy. As our 
preoperative chemotherapy protocol was the same for 
all patients and no other factors such as age, gender, 
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and so forth in this study we found to have significant 
effect on postoperative chemotherapy, so it seems that 
the degree of necrosis at the time of surgery is reflected 
by inherent properties of some tumors that make them 
intrinsically less responsive to chemotherapy. The 
property of tumor itself, or the effectiveness of the kind 
of combined chemotherapy drugs should be considered 
in the neoadjuvant treatment.
In conclusion, the demographic parameter of 
patients at presentation seems to play an important role 
in prognosis , however, the more important factor in 
prediction of prognosis is available during the therapeutic 
plan, especially when tissue response to chemotherapy 
is determined. Although in our study the length of 
follow up was short yet it is notable to say that there 
was not such an even short study about osteosarcoma 
of extremities, and its demographic variables in Iran. 
This study will be continued to more than 10 years of 




  1. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco 
JB, et al. The effect of adjuvant chemotherapy on relapse - free 
survival in patients with osteosarcoma of the extremity. N Engl 
J Med 1986; 314: 1600-1606.
  2. Rosen G, Nirenberg A, Caparros B. Osteosarcoma: Eighty 
percent, three year, disease free survival with combination 
chemotherapy (T7). Natl Cancer Inst Monogr 1981; 56: 
213-220. 
  3. Rosen G, Nirenberg A, Caparros B. Preoperative chemotherapy 
for osteogenic sarcoma: selection of post operative adjuvant 
chemotherapy based on the response of the primary tumor to 
preoperative chemotherapy. Cancer 1982; 49: 1221-1238.
  4. Winkler K, Beron G, Kotz R. Neoadjuvant chemotherapy for 
osteosarcoma: results of a cooperative German/Austrian study. J 
Clin Oncol 1984; 2: 617-623.
  5. Krailo M, Ertle I, Makly J. A randomized study comparing 
high-dose methotrexate with moderate-dose methotrexate 
as components of adjuvant chemotherapy in childhood 
nonmetastatic osteosarcoma: a report from children’s cancer 
study group. Med Pediatr Oncol 1987; 15: 69-77.
   6. Goorin AM, Perez-Atayde A, Gebhardt M, Andersen 
JW, Wilkinson RH, Delorey MJ, et al. Weekly high dose 
methotrexate and doxorubicin for osteosarcoma: the Dana 
-Farber Cancer Institute/the Children’s HSospital-study III. J 
Clin Oncol 1987; 5: 1178-1184.
  7. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst 
C, et al. Neoadjuvant chemotherapy for osteosarcoma results 
of a randomized cooperative trial (COSS-82) with salvage 
chemotherapy. J Clin Oncol 1988; 6: 329-337.
  8. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, 
et al. Primary chemotherapy and delayed surgery (neoadjuvant 
chemotherapy) for osteosarcoma of the extremities. The Instituto 
Rizzoli Experience in 127 patients treated preoperatively with 
intravenous methotrexate (high versus moderate doses) and 
intraarterial cisplatin. Cancer 1990; 65: 2539-2553.
  9. French Bone Tumor Study Group. Age and dose of 
chemotherapy as major prognostic factor in trial of adjuvant 
therapy of osteosarcoma combining two alternating drug 
combinations and early prophylactic lung irradiation. Cancer 
1988; 61: 1304-1311.
10. Meyers PA, Heller G, Healey J.  Chemotherapy for nonmetastatic 
osteogenic sarcoma: the Memorial Sloan-Kettering experience. 
J Clin Oncol 1992; 10: 5-15.
11. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom 
AT, Voûte PA, et al. A comparison of two short intensive 
adjuvant chemotherapy regimens in operable osteosarcoma of 
limbs in children and young adults: the first study of European 
osteosarcoma intergroup. J Clin Oncol 1992; 10: 1579-1591.
12. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et 
al. Primary chemotherapy and delayed surgery for nonmetastatic 
osteosarcoma of the extremities: results in 164 patients 
preoperatively treated with high doses of methotrexate followed 
by doxorubicin and cisplatin. Cancer 1993; 72: 3227-3228.
13. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, 
Yunis EJ, et al. Treatment of nonmetastatic osteosarcoma of the 
extremity with pre and postoperative chemotherapy: A report 
from children’s cancer group. J Clin Oncol 1997; 15: 79-84.
14. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, 
Spooner D, Bramwell VH, et al. Randomized trial of two 
regimens of chemotherapy in operable osteosarcoma: A study 
of the European osteosarcoma intergroup. Lancet 1997; 350: 
911-917.
15. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Körholz D, 
et al. Longterm results of German-Austrian-Swiss osteosarcoma 
study group protocol COSS-86 of intensive multidrug 
chemotherapy and surgery for osteosarcoma of the limbs. Ann 
Oncol 1998; 9: 893-899. 
16. Bielack S, Kempf B, Schwenzer D. Neoadjuvant therapy des 
lokali sierten osteosarkoms der extremetaten. Erfahrunger der 
cooperativen osteosarkomstudiengruppe coss an 925 patienem. 
Klin Padiatr 1999; 211: 260-270.
17. Huvos A. Osteosarcoma: Pathologic assessment of preoperative 
(neoadjuvant) chemotherapy. In bone tumors: diagnosis, 
treatment, and prognosis. 2nd ed. Philadelphia (PA): W.B. 
Saunders; 1991. p. 122-128.
18. Rosen G, Caparrs B, Huvos A, Kosloff C, Nirenbeerg A, 
Cacavio A, et al. Preoperative chemotherapy for osteosarcoma :
selection of postoperative adjuvant chemotherapy based on the 
response of the primary tumor to preoperative chemotherapy. 
Cancer 1982; 49: 1221-1230.
19. Sprringfield D, Schakel M, Spanier S. Spontanous necrosis in 
osteosarcoma. Clin Orthop 1991; 263: 233-237.
20. Bacci G, Picci P, Pignatti G, De Cristofaro R, Dallari D, 
Avella M, et al. Neoadjuvant chemotherapy for nonmetastatic 
osteosarcoma of the extremities. Clin Orthop 1991; 270: 
87-98.
21. Meyers PA, Gorlick R, Healy J. Intensification of preoperative 
chemotherapy for osteosarcoma: results of memorial Sloan_
Kettering T12 protocol. J Clin Oncol 1998; 162: 2452-2458.
22. Picci P, Sangiorgi L, Rougraff B, Neff J. Relationship of 
chemotherapy-induced necrosis and surgical margins to 
local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 
2699-2705.
23. Arndt CA, Crist WM. Common musculoskeletal tumors of 
childhood and adolescence. N Engl J Med 1999; 341: 342-
352.
24. Hutchins LF, Unger  JM, Crowley JJ. Underrepresentation of 
patients 65 years of age or older in cancer treatment trials. N 
Engl J Med 1999; 341: 2061-2067.
1129www. smj.org.sa     Saudi Med J 2008; Vol. 29 (8) 
Tissue necrosis after chemotherapy in osteosarcoma ... Sami et al
25. Davis AM, Bell RS, Goodvin PJ. Prognositic factors in 
osteosarcoma: a critical review. J Clin Oncol 1994; 12: 
423-431.
26. Bieling P, Rehan N, Winkler P. Tumor size and prognosis in 
aggressively treated osteosarcoma. J Clin Oncol 1996; 14: 848-
858. 
27. Saeter G, Elomaa I, Wahlqvist Y, Alvegård TA, Wiebe T, Monge 
O, et al. Prognostic factors in bone sarcomas. Acta Orthop 
Scand Suppl 1997; 273: 156-160.
28. Winkler K, Beron G, Schellong G. Cooperative 
osteosarkomstudie coss_77: Ergebnisse nach uber 4 Jahren. 
Klin Padiatr 1982; 194: 251-256.
29. Bacci G, Ferrari. Prognostic significance of serum alkaline 
phosphatase measurements in patients with osteosarcoma 
treated with adjuvant or neoadjuvant chemotherapy. Cancer 
1993; 71:1224-1230.
30. Bacci G, Ferrari S. Prognostic significance of serum lactate 
dehydrogenase in patients with osteosarcoma of the extremities. 
J Chemother 1995; 6: 204-210.
31. Bacci G, Picci P, Ferrari S. Influence of adriamycin dose in the 
outcome of patients with osteosarcoma treated with multidrug 
neoadjuvant chemotherapy: Results of two sequencial studies. J 
Chemother 1993; 5: 237-246.
32. Benjamin RS, Patel SR, Armen T. The value of isofosfamide in 
postoperative neoadjuvant chemotherapy of osteosarcoma. Proc 
Am Soc Clin Oncol 1995; 14: 516. 
33. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, 
Mathé G. Importance of age and methotrexate dosage: prognosis 
in children and young adults with high-grade osteosarcomas. 
Biomed Pharmacother 1988;42: 257-262.
34. Provisor AJ, Ettinger LJ, Nachman JB. Treatment of 
nonmetastatic osteosarcoma of the extremity with pre and 
postoperative chemotherapy. A report from the children’s cancer 
group. J Clin Oncol 1997; 15: 76-84.
35. Saeter G, Alvegrad TA, Elomaa I. Treatment of osteosarcoma 
of  the extremities with the t-10 protocol, with emphasis of the 
effects of preoperative chemotherapy with single agent high 
dose methotrexate: A Scandivian Sarcoma Group Study. J Clin 
Oncol 1991; 9: 1766-1775. 
36. Bacci G, Ferrari S, Delepine N. Predictive factors of the 
histologic response to primary chemotherapy in osteosarcoma 
of the extremity: study of 272 patients preoperatively treated 
with high dose methotrexate doxorubicine and cisplatin. J Clin 
Oncol 1998; 16: 658-663. 
37. Goldie JH, Coldman AJ. A mathematical model for relating the 
drug  sensitivity of tumors to their spontaneous mutation rate. 
Cancer Treat Rep 1979; 63: 1727-1733.
Copyright
Whenever a manuscript contains material (tables, figures, etc.) which is 
protected by copyright (previously published), it is the obligation of the 
author to obtain written permission from the holder of the copyright (usually 
the publisher) to reproduce the material in Saudi Medical Journal. This also 
applies if the material is the authors own work. Please submit copies of the 
material from the source in which it was first published.
View publication stats
